FUJIFILM Diosynth Biotechnologies Ink 10-Year Manufacturing Supply Agreement Worth $3B With Regeneron Pharmaceuticals
REGNApril 22, 2025
Read more →Reported Friday, Regeneron Receives FDA Complete Response On EYLEA HD Application, No Safety Or Efficacy Issues Identified
REGNApril 21, 2025
Read more →Regeneron Pharmaceuticals And Sanofi Announce FDA Approval of Dupixent For Chronic Spontaneous Urticaria in Adults and Adolescents
REGNApril 18, 2025
Read more →FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion
REGNFDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.
April 17, 2025
Read more →Canaccord Genuity Maintains Hold on Regeneron Pharmaceuticals, Lowers Price Target to $150
REGNApril 17, 2025
Read more →Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts
REGNApril 17, 2025
Read more →B of A Securities Maintains Underperform on Regeneron Pharmaceuticals, Lowers Price Target to $547
REGNApril 17, 2025
Read more →FDA Accepts Regeneron's EYLEA HD Injection 8 mg sBLA For Priority Review For Treatment Of Macular Edema Following Retinal Vein Occlusion And For Monthly Dosing In Approved Indications
REGNApril 17, 2025
Read more →Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study
REGNSanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.
April 15, 2025
Read more →Goldman Sachs Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $917
REGNApril 14, 2025
Read more →Is Regeneron Pharmaceuticals Gaining or Losing Market Support?
REGNApril 9, 2025
Read more →JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1000
REGNMarch 31, 2025
Read more →$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
REGNMarch 28, 2025
Read more →Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors
REGNSensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.
March 28, 2025
Read more →Regeneron And Sanofi's Dupixent Receives Japan's First Biologic Approval For Patients With Chronic Obstructive Pulmonary Disease (COPD)
REGNMarch 28, 2025
Read more →Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
REGNUnity diabetes study showing durable vision gains with full 36-week data expected in Q2 2025.
March 24, 2025
Read more →Price Over Earnings Overview: Regeneron Pharmaceuticals
REGNMarch 18, 2025
Read more →If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
REGNMarch 11, 2025
Read more →Regeneron Says EMA CHMP Adopted Positive Opinion Recommending Conditional Marketing Authorization Of Linvoseltamab To Treat Adults With Relapsed And Refractory Multiple Myeloma
REGNFebruary 28, 2025
Read more →Regeneron Says EMA's CHMP Adopted Positive Opinion Recommending Conditional Marketing Authorization Of Linvoseltamab In Relapsed/Refractory Multiple Myeloma
REGNFebruary 28, 2025
Read more →FDA Accepts Odronextamab BLA For Review In R/R Follicular Lymphoma, Decision Expected By July 30, 2025
REGNFebruary 26, 2025
Read more →Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss
REGNRegeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching near-normal levels at 24 weeks.
February 25, 2025
Read more →Regeneron Pharmaceuticals Presents Latest DB-OTO Results, Says Demonstrate Clinically Meaningful Hearing Improvements In Nearly All Children With Profound Genetic Hearing Loss In CHORD Trial; As Presented At ARO, 10 Of 11 Children With At Least One Post-T
REGNFebruary 24, 2025
Read more →Price Over Earnings Overview: Regeneron Pharmaceuticals
REGNFebruary 21, 2025
Read more →Regeneron And Sanofi Announce FDA Priority Review For Dupixent In Bullous Pemphigoid, With Approval Decision Expected By June 2025
REGNFebruary 18, 2025
Read more →Looking Into Regeneron Pharmaceuticals's Recent Short Interest
REGNFebruary 17, 2025
Read more →Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
REGNFebruary 14, 2025
Read more →Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030
REGNRegeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.
January 14, 2025
Read more →Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $795
REGNJanuary 14, 2025
Read more →Live On CNBC, Rob Sechan Announces Sold Regeneron
REGNJanuary 13, 2025
Read more →Regeneron's Libtayo Extends Disease-Free Survival in High-Risk Skin Cancer Patients After Surgery
REGNJanuary 13, 2025
Read more →Regeneron Partners with Truveta, Invests $119.5M to Launch Genome Project Linking DNA and Health Data
REGNJanuary 13, 2025
Read more →Forecasting The Future: 22 Analyst Projections For Regeneron Pharmaceuticals
REGNJanuary 10, 2025
Read more →Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $900
REGNJanuary 10, 2025
Read more →If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
REGNDecember 23, 2024
Read more →Regeneron Reports Phase 2 Results For Two Novel Monoclonal Antibodies Targeting Distinct Domains Of Factor XI; Says There Was Antithrombotic Effect For Each Antibody; Phase 3 Program To Be Initiated In 2025
REGNDecember 19, 2024
Read more →Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
REGNNovember 19, 2024
Read more →Peering Into Regeneron Pharmaceuticals's Recent Short Interest
REGNNovember 18, 2024
Read more →Check Out What Whales Are Doing With REGN
REGNNovember 15, 2024
Read more →FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
REGNRegeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025.
November 15, 2024
Read more →Wolfe Research Initiates Coverage On Regeneron Pharmaceuticals with Outperform Rating, Announces Price Target of $1150
REGNNovember 15, 2024
Read more →Dupixent's sBLA Resubmission Accepted By FDA; Phase 3 Data Demonstrate Significant Itch And Hive Reduction For Chronic Urticaria Patients
REGNNovember 15, 2024
Read more →28 Analysts Have This To Say About Regeneron Pharmaceuticals
REGNNovember 14, 2024
Read more →Citigroup Initiates Coverage On Regeneron Pharmaceuticals with Neutral Rating, Announces Price Target of $895
REGNNovember 14, 2024
Read more →Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
REGNNovember 6, 2024
Read more →Oppenheimer Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1000
REGNNovember 6, 2024
Read more →Regeneron And Sanofi's Dupixent Receives EU Approval For Children With Eosinophilic Esophagitis, Offering New Hope For Ages 1 To 11
REGNNovember 6, 2024
Read more →This Is What Whales Are Betting On Regeneron Pharmaceuticals
REGNNovember 4, 2024
Read more →Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1184
REGNNovember 1, 2024
Read more →RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1215
REGNNovember 1, 2024
Read more →